Aberrant expression of TRAIL in B chronic lymphocytic leukemia (B-CLL) cells

Paola Secchiero, Mario Tiribelli, Elisa Barbarotto, Claudio Celeghini, Angela Michelutti, Paola Masolini, Renato Fanin, Giorgio Zauli

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Analysis of peripheral blood (>85% CD19+/CD5+ B) lymphocytes, obtained from 44 patients affected by B chronic lymphoid leukemia (B-CLL), showed that surface TNF-related apoptosis inducing ligand (TRAIL) was expressed in all samples and at higher levels with respect to unfractionated lymphocytes and purified CD19+ B cells, obtained from 15 normal blood donors. Of note, in a subset of B-CLL samples, the addition to B-CLL cultures of a TRAIL-R1-Fc chimera, which binds at high affinity to surface TRAIL, significantly decreased the percentage of viable cells with respect to untreated control B-CLL cells, suggesting that surface TRAIL may play an unexpected role in promoting B-CLL cell survival. In spite of the majority of B-CLL lymphocytes expressed variable surface levels of "death receptors" TRAIL-R1 and TRAIL-R2, the addition in culture of recombinant TRAIL increased (>20% vs. controls) the degree of spontaneous apoptosis in only 11/44 of the B-CLL samples, had no effect in 19/44, while it significantly increased leukemic cell survival in 14/44. Taken together, these findings suggest that an aberrant expression of TRAIL might contribute to the pathogenesis of B-CLL by promoting the survival in a subset of B-CLL cells.

Original languageEnglish
Pages (from-to)246-252
Number of pages7
JournalJournal of Cellular Physiology
Volume205
Issue number2
DOIs
Publication statusPublished - Nov 2005

Fingerprint

TNF-Related Apoptosis-Inducing Ligand
B-Cell Chronic Lymphocytic Leukemia
Lymphocytes
Cells
Cell Survival
Blood
B-Lymphocytes
Lymphoid Leukemia
Death Domain Receptors
Blood Donors
Apoptosis
Survival

ASJC Scopus subject areas

  • Cell Biology
  • Clinical Biochemistry
  • Physiology

Cite this

Secchiero, P., Tiribelli, M., Barbarotto, E., Celeghini, C., Michelutti, A., Masolini, P., ... Zauli, G. (2005). Aberrant expression of TRAIL in B chronic lymphocytic leukemia (B-CLL) cells. Journal of Cellular Physiology, 205(2), 246-252. https://doi.org/10.1002/jcp.20392

Aberrant expression of TRAIL in B chronic lymphocytic leukemia (B-CLL) cells. / Secchiero, Paola; Tiribelli, Mario; Barbarotto, Elisa; Celeghini, Claudio; Michelutti, Angela; Masolini, Paola; Fanin, Renato; Zauli, Giorgio.

In: Journal of Cellular Physiology, Vol. 205, No. 2, 11.2005, p. 246-252.

Research output: Contribution to journalArticle

Secchiero, P, Tiribelli, M, Barbarotto, E, Celeghini, C, Michelutti, A, Masolini, P, Fanin, R & Zauli, G 2005, 'Aberrant expression of TRAIL in B chronic lymphocytic leukemia (B-CLL) cells', Journal of Cellular Physiology, vol. 205, no. 2, pp. 246-252. https://doi.org/10.1002/jcp.20392
Secchiero P, Tiribelli M, Barbarotto E, Celeghini C, Michelutti A, Masolini P et al. Aberrant expression of TRAIL in B chronic lymphocytic leukemia (B-CLL) cells. Journal of Cellular Physiology. 2005 Nov;205(2):246-252. https://doi.org/10.1002/jcp.20392
Secchiero, Paola ; Tiribelli, Mario ; Barbarotto, Elisa ; Celeghini, Claudio ; Michelutti, Angela ; Masolini, Paola ; Fanin, Renato ; Zauli, Giorgio. / Aberrant expression of TRAIL in B chronic lymphocytic leukemia (B-CLL) cells. In: Journal of Cellular Physiology. 2005 ; Vol. 205, No. 2. pp. 246-252.
@article{94ba2ab53a124612a24ecf1773ec91b2,
title = "Aberrant expression of TRAIL in B chronic lymphocytic leukemia (B-CLL) cells",
abstract = "Analysis of peripheral blood (>85{\%} CD19+/CD5+ B) lymphocytes, obtained from 44 patients affected by B chronic lymphoid leukemia (B-CLL), showed that surface TNF-related apoptosis inducing ligand (TRAIL) was expressed in all samples and at higher levels with respect to unfractionated lymphocytes and purified CD19+ B cells, obtained from 15 normal blood donors. Of note, in a subset of B-CLL samples, the addition to B-CLL cultures of a TRAIL-R1-Fc chimera, which binds at high affinity to surface TRAIL, significantly decreased the percentage of viable cells with respect to untreated control B-CLL cells, suggesting that surface TRAIL may play an unexpected role in promoting B-CLL cell survival. In spite of the majority of B-CLL lymphocytes expressed variable surface levels of {"}death receptors{"} TRAIL-R1 and TRAIL-R2, the addition in culture of recombinant TRAIL increased (>20{\%} vs. controls) the degree of spontaneous apoptosis in only 11/44 of the B-CLL samples, had no effect in 19/44, while it significantly increased leukemic cell survival in 14/44. Taken together, these findings suggest that an aberrant expression of TRAIL might contribute to the pathogenesis of B-CLL by promoting the survival in a subset of B-CLL cells.",
author = "Paola Secchiero and Mario Tiribelli and Elisa Barbarotto and Claudio Celeghini and Angela Michelutti and Paola Masolini and Renato Fanin and Giorgio Zauli",
year = "2005",
month = "11",
doi = "10.1002/jcp.20392",
language = "English",
volume = "205",
pages = "246--252",
journal = "Journal of cellular and comparative physiology",
issn = "0021-9541",
publisher = "Wiley-Liss Inc.",
number = "2",

}

TY - JOUR

T1 - Aberrant expression of TRAIL in B chronic lymphocytic leukemia (B-CLL) cells

AU - Secchiero, Paola

AU - Tiribelli, Mario

AU - Barbarotto, Elisa

AU - Celeghini, Claudio

AU - Michelutti, Angela

AU - Masolini, Paola

AU - Fanin, Renato

AU - Zauli, Giorgio

PY - 2005/11

Y1 - 2005/11

N2 - Analysis of peripheral blood (>85% CD19+/CD5+ B) lymphocytes, obtained from 44 patients affected by B chronic lymphoid leukemia (B-CLL), showed that surface TNF-related apoptosis inducing ligand (TRAIL) was expressed in all samples and at higher levels with respect to unfractionated lymphocytes and purified CD19+ B cells, obtained from 15 normal blood donors. Of note, in a subset of B-CLL samples, the addition to B-CLL cultures of a TRAIL-R1-Fc chimera, which binds at high affinity to surface TRAIL, significantly decreased the percentage of viable cells with respect to untreated control B-CLL cells, suggesting that surface TRAIL may play an unexpected role in promoting B-CLL cell survival. In spite of the majority of B-CLL lymphocytes expressed variable surface levels of "death receptors" TRAIL-R1 and TRAIL-R2, the addition in culture of recombinant TRAIL increased (>20% vs. controls) the degree of spontaneous apoptosis in only 11/44 of the B-CLL samples, had no effect in 19/44, while it significantly increased leukemic cell survival in 14/44. Taken together, these findings suggest that an aberrant expression of TRAIL might contribute to the pathogenesis of B-CLL by promoting the survival in a subset of B-CLL cells.

AB - Analysis of peripheral blood (>85% CD19+/CD5+ B) lymphocytes, obtained from 44 patients affected by B chronic lymphoid leukemia (B-CLL), showed that surface TNF-related apoptosis inducing ligand (TRAIL) was expressed in all samples and at higher levels with respect to unfractionated lymphocytes and purified CD19+ B cells, obtained from 15 normal blood donors. Of note, in a subset of B-CLL samples, the addition to B-CLL cultures of a TRAIL-R1-Fc chimera, which binds at high affinity to surface TRAIL, significantly decreased the percentage of viable cells with respect to untreated control B-CLL cells, suggesting that surface TRAIL may play an unexpected role in promoting B-CLL cell survival. In spite of the majority of B-CLL lymphocytes expressed variable surface levels of "death receptors" TRAIL-R1 and TRAIL-R2, the addition in culture of recombinant TRAIL increased (>20% vs. controls) the degree of spontaneous apoptosis in only 11/44 of the B-CLL samples, had no effect in 19/44, while it significantly increased leukemic cell survival in 14/44. Taken together, these findings suggest that an aberrant expression of TRAIL might contribute to the pathogenesis of B-CLL by promoting the survival in a subset of B-CLL cells.

UR - http://www.scopus.com/inward/record.url?scp=26444435775&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=26444435775&partnerID=8YFLogxK

U2 - 10.1002/jcp.20392

DO - 10.1002/jcp.20392

M3 - Article

VL - 205

SP - 246

EP - 252

JO - Journal of cellular and comparative physiology

JF - Journal of cellular and comparative physiology

SN - 0021-9541

IS - 2

ER -